Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Carbapenem-Based Antibiotics Market Growth in 2025?

In recent times, a steady growth has been observed in the market size of carbapenem-based antibiotics. The market, which is set to grow from $4.6 billion in 2024 to $4.82 billion in 2025, is expected to register a compound annual growth rate (CAGR) of 4.8%. Factors such as an increase in pandemics and epidemics, a surge in chronic illnesses, enhancements in healthcare infrastructure, quick urbanization, and persistent health emergencies and natural disasters have contributed to the growth experienced during the historic period.

What Is the Forecast for the Carbapenem-Based Antibiotics Market Size Through 2029?

The market size of carbapenem-based antibiotics is projected to witness significant expansion in the upcoming years, expected to reach $6.09 billion by 2029 with a compound annual growth rate (CAGR) of 6.0%. Factors contributing to the growth in the forecast period include a steep rise in hospital-acquired infections, the advent of multi-drug resistant strains, an expanding elderly population, increase in surgical procedures, spread of infectious diseases, and shifting demographics. The forecast period will also observe prevalent trends including enhanced resilience and security of supply chains, development of alternative treatments, a shift towards outpatient settings, an increasing awareness of antimicrobial stewardship, and precision medicine approaches.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12035&type=smp

What are the Key Market Players in Carbapenem-Based Antibiotics Market and How They’re Evolving?

Major companies operating in the carbapenem-based antibiotics market include Pfizer Inc., Merck & Co. Inc., Fresenius Kabi LLC, GlaxoSmithKline Plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Meiji Holdings Co. Ltd., Sandoz International GmbH, Sumitomo Dainippon Pharma Co. Ltd., Shionogi & Co Ltd., Aurobindo Pharma Ltd., Acurx Pharmaceuticals LLC, Daewoong Pharmaceutical Co. Ltd., CeramTec GmbH, ACS Dobfar S.p.A, JW Pharmaceutical Corp, Centrient Pharmaceuticals Co, Spero Therapeutics Inc., Kopran Limited, Savior Lifetec Corporation, Flagship Biotech International Pvt. Ltd., Iterum Therapeutics plc, Cam Carbapenem-based antibiotics BV, Intelicure Lifesciences, Ikeda Corporation

What Are the Primary Growth Drivers in the Carbapenem-Based Antibiotics Market?

The upward trend in bacterial infections is projected to boost the development of the carbapenem-based antibiotics market. These infections are induced by bacteria, tiny organisms that can infiltrate the human body and trigger numerous diseases and symptoms. Antibiotics based on carbapenem are used to deal with serious or multidrug-resistant bacterial infections, which include infections from gram-positive and gram-negative bacteria. For example, a report released in July 2024 by the Centers for Disease Control and Prevention, a U.S. government agency, found that 78% of all bacterial infections in the historic catchment area were identified using CIDTs in 2023, including 46% that were diagnosed exclusively with CIDTs. Hence, the escalating occurrence of bacterial infections is driving the expansion of the carbapenem-based antibiotics market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12035&type=smp

What Are the Leading Segments in the Global Carbapenem-Based Antibiotics Industry?

The carbapenem-based antibiotics market covered in this report is segmented –

1) By Type: Meropenem, Imipenem, Doripenem, Tebipenem, Other Types

2) By Indication: Intra-abdominal Infections, Urinary Tract Infections, Pneumonia, Bacterial Meningitis, Skin And Skin Structure Infections, Acute Pelvic Infections, Prophylaxis of Surgical Site Infection, Respiratory Tract Infections, Gynecological Infections, Other Indications

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Meropenem: Meropenem Injection, Meropenem and Vaborbactam Combination, Meropenem for Pediatric Use

2) By Imipenem: Imipenem and Cilastatin Combination, Imipenem and Relebactam Combination, Imipenem Monotherapy

3) By Doripenem: Doripenem Injection, Doripenem for Complicated Infections

4) By Tebipenem: Tebipenem for Oral Administration, Tebipenem Pediatric Formulations, Tebipenem for Resistant Infections

5) By Other Types: Ertapenem, Panipenem, Faropenem, Combinations with Beta-Lactamase Inhibitors

What Are the Key Market Trends in the Carbapenem-Based Antibiotics Industry?

Innovation in products forms the predominant trend in the carbapenem-based antibiotics market as leading corporations strive to retain their market presence via product enhancements. Case in point, the UK-based government organization, National Health Service (NHS), in August 2024, spearheaded a groundbreaking subscription scheme for antibiotics. Developed in conjunction with the pharmaceutical industry, it is designed to address antimicrobial resistance (AMR). Officially announced on August 12, 2024, this forward-thinking model enables pharmaceutical companies to earn fixed annual fees of up to £20 million per drug, irrespective of the prescription volume, thus eliminating rewards for excessive use. The project, which is estimated to be worth around £1.9 billion over a span of 16 years, is intended to stimulate the production of novel antibiotics by guaranteeing financial feasibility to pharmaceutical organizations. After a triumphant trial phase, this initiative constitutes a component of the UK’s comprehensive plan to combat AMR. If not dealt with, AMR could become a major global health hazard, potentially leading to millions of fatalities by 2050. The NHS will focus on products that target critical pathogens as identified by the World Health Organization, reaffirming its commitment to responsible antibiotic management while also promoting innovation in antibiotic development.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/carbapenem-based-antibiotics-global-market-report

What Is the Regional Outlook for the Carbapenem-Based Antibiotics Market?

North America was the largest region in the Carbapenem-Based Antibiotics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carbapenem-based antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12035

This Report Delivers Insight On:

1. How big is the carbapenem-based antibiotics market, and how is it changing globally?

2. Who are the major companies in the carbapenem-based antibiotics market, and how are they performing?

3. What are the key opportunities and risks in the carbapenem-based antibiotics market right now?

4. Which products or customer segments are growing the most in the carbapenem-based antibiotics market?

5. What factors are helping or slowing down the growth of the carbapenem-based antibiotics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model